Method for improving the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or its salt using an inhibitor of cytochrome P450

Abstract

Described herein are compositions comprising (a) methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate, or a salt thereof, and (b) an agent for decreasing the metabolism of (a), and uses thereof.

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 62 / 959,514, filed January 10, 2020, the entire contents of which are incorporated herein by reference. [Background technology]

[0002] Orexin (OX) is a neuropeptide that regulates sleep / wake states and is involved in energy homeostasis, mood, stress, and reward through activation of two G protein-coupled receptors, OX1R and OX2R. OX2R agonists directly target the underlying disease pathophysiology of narcolepsy type 1 (NT1) by restoring OX2R receptor signaling in these patients who lack endogenous OX. Methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate showed significant effects on improving wakefulness and reducing cataplexy-like symptoms in rodent models of narcolepsy and promoted wakefulness in both healthy mice and nonhuman primates.

[0003] Methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate was the first OX2R agonist to enter human studies and was shown to be safe and well tolerated when administered intravenously (IV) in single-dose studies in both healthy volunteers and NT1 patients. Summary of the Invention

[0004] One embodiment is a combination therapy comprising (a) an orexin type 2 receptor (OX2R) agonist, and (b) an agent for decreasing the metabolism of the OX2R agonist, compositions and kits comprising the combination therapy, and methods of using the combination therapy.

[0005] Another embodiment is a method for improving the pharmacokinetics of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof, comprising administering to a subject: (a) methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof; and (b) an agent for decreasing the metabolism of (a).

[0006] Another embodiment is a method for increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof, comprising administering to a subject: (a) methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof; and (b) an agent for decreasing the metabolism of (a).

[0007] Another embodiment is a method of increasing wakefulness or reducing excessive sleepiness in a subject in need thereof, comprising administering to the subject (a) methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof, and (b) an agent for decreasing the metabolism of (a).

[0008] Another embodiment is a pharmaceutical composition comprising (a) methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate, or a salt thereof, and (b) an agent for decreasing the metabolism of (a). [Brief explanation of the drawings]

[0009] [Figure 1] 1 shows a schematic diagram of the test in Example 1. [Figure 2]Figure 1 shows a graph of dose-normalized arithmetic mean plasma Compound A concentrations (relative to the 112 mg Compound A dose) versus time in healthy subjects after a single 14 mg dose of Compound A alone was administered intravenously over 9 hours on day 2, a single 112 mg oral dose of Compound A alone on day 3, and a single 14 mg oral dose of Compound A on day 12 co-administered with multiple 150 mg oral doses of cobicistat once daily on days 5-13. [Figure 3] Figure 1 shows the arithmetic mean plasma Compound A concentrations over time in healthy subjects after a single 14 mg dose of Compound A alone administered intravenously over 9 hours on day 2, a single 112 mg oral dose of Compound A alone on day 3, and a single 14 mg oral dose of Compound A on day 12 co-administered with multiple 150 mg once-daily oral doses of cobicistat on days 5-13. DETAILED DESCRIPTION OF THE INVENTION

[0010] Disclosed herein are combination therapies, compositions and kits comprising the combination therapies, and methods of using the combination therapies, comprising (a) an orexin type 2 receptor (OX2R) agonist and (b) an agent for reducing the metabolism of the OX2R agonist. Suitable OX2R agonists include, but are not limited to, those disclosed in WO2017 / 135306, the contents of which are hereby incorporated by reference.

[0011] Disclosed herein are combination therapies comprising (a) methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof (hereinafter, "Compound (I)"), and (b) an agent for reducing the metabolism of Compound (I), compositions and kits comprising the combination therapy, and methods of using the combination therapy. In particular, the present invention can improve the bioavailability of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate, which has extensive first-pass metabolism.

[0012] The methods, compositions, and uses disclosed herein include treating diseases, disorders, or symptoms associated with excessive sleepiness in subjects in need thereof, as well as treating subjects who have not been diagnosed with any disease or disorder but who suffer from excessive sleepiness. Multiple causes are attributed to excessive sleepiness, including, but not limited to, abnormal sleep quantity or quality, and neurological, psychological, cardiac, and pulmonary disorders.

[0013] In one embodiment, the methods, compositions, and uses of the present disclosure may relate to treating excessive sleepiness caused by a lack of the neuropeptide OX, which regulates wakefulness, alertness, and appetite. Excessive sleepiness can also occur in individuals who do not have an orexin deficiency. The present disclosure also relates to treating diseases, disorders, and / or symptoms of excessive sleepiness that are not associated with reduced orexin levels.

[0014] Disclosed herein is a method for improving the pharmacokinetics of Compound (I), the method comprising administering to a subject: (a) Compound (I); and (b) an agent for decreasing the metabolism of Compound (I).

[0015] Further disclosed herein is a combination therapy for use in improving the pharmacokinetics of Compound (I), comprising (a) Compound (I) and (b) an agent for decreasing the metabolism of Compound (I).

[0016] Further disclosed herein is the use of (a) Compound (I), and (b) an agent for decreasing the metabolism of Compound (I), in the manufacture of a medicament for improving the pharmacokinetics of Compound (I).

[0017] Further disclosed herein is an agent for decreasing the metabolism of Compound (I), for use in improving the pharmacokinetics of Compound (I).

[0018] Further disclosed herein is the use of an agent for decreasing the metabolism of Compound (I) in the manufacture of a medicament for improving the pharmacokinetics of Compound (I).

[0019] Disclosed herein is a method for increasing the plasma concentration of Compound (I), comprising administering to a subject: (a) Compound (I); and (b) an agent for decreasing the metabolism of Compound (I).

[0020] Further disclosed herein is a combination therapy for use in increasing the plasma concentration of Compound (I), comprising: (a) Compound (I); and (b) an agent for decreasing the metabolism of Compound (I).

[0021] Further disclosed herein is the use of (a) Compound (I), and (b) an agent for decreasing the metabolism of Compound (I), in the manufacture of a medicament for increasing the plasma concentration of Compound (I).

[0022] Further disclosed herein is an agent for decreasing the metabolism of Compound (I), for use in increasing the plasma concentration of Compound (I).

[0023] Further disclosed herein is the use of an agent for decreasing the metabolism of Compound (I) in the manufacture of a medicament for increasing the plasma concentration of Compound (I).

[0024] Disclosed herein is a method for maintaining the pharmaceutical effect of Compound (I), comprising administering to a subject: (a) Compound (I); and (b) an agent for decreasing the metabolism of Compound (I).

[0025] Further disclosed herein is a combination therapy comprising (a) Compound (I) and (b) an agent for decreasing the metabolism of Compound (I) for use in maintaining the pharmaceutical effect of Compound (I).

[0026] Further disclosed herein is the use of (a) Compound (I), and (b) an agent for decreasing the metabolism of Compound (I), in the manufacture of a medicament for maintaining the pharmaceutical action of Compound (I).

[0027] Disclosed herein is a method for maintaining a pharmaceutically effective plasma concentration of Compound (I), the method comprising administering to a subject: (a) Compound (I); and (b) an agent for decreasing the metabolism of Compound (I).

[0028] Further disclosed herein is a combination therapy for use in maintaining a pharmaceutically effective plasma concentration of Compound (I), comprising: (a) Compound (I); and (b) an agent for decreasing the metabolism of Compound (I).

[0029] Further disclosed herein is the use of (a) Compound (I), and (b) an agent for decreasing the metabolism of Compound (I), in the manufacture of a medicament for maintaining a pharmaceutically effective plasma concentration of Compound (I).

[0030] Disclosed herein is a method for decreasing the metabolism of Compound (I), the method comprising administering to a subject: (a) Compound (I); and (b) a CYP3A inhibitor.

[0031] Further disclosed herein is a combination therapy comprising (a) Compound (I) and (b) a CYP3A inhibitor for use in decreasing the metabolism of Compound (I).

[0032] Further disclosed herein is the use of (a) Compound (I), and (b) a CYP3A inhibitor in the manufacture of a medicament for decreasing the metabolism of Compound (I).

[0033] Disclosed herein is a method for reducing the time-dependent decline in plasma concentration of Compound (I), the method comprising administering to a subject: (a) Compound (I); and (b) a CYP3A inhibitor.

[0034] Further disclosed herein is a combination therapy comprising (a) Compound (I) and (b) a CYP3A inhibitor for use in attenuating the time-dependent decline in plasma concentrations of Compound (I).

[0035] Further disclosed herein is the use of (a) Compound (I), and (b) a CYP3A inhibitor in the manufacture of a medicament for attenuating the time-dependent decline in plasma concentration of Compound (I).

[0036] Disclosed herein is a method for decreasing the metabolism of Compound (I), the method comprising administering to a subject (a) Compound (I) and (b) a CYP3A4 inhibitor.

[0037] Further disclosed herein is a combination therapy comprising (a) Compound (I) and (b) a CYP3A4 inhibitor for use in decreasing the metabolism of Compound (I).

[0038] Further disclosed herein is the use of (a) Compound (I), and (b) a CYP3A4 inhibitor in the manufacture of a medicament for decreasing the metabolism of Compound (I).

[0039] Disclosed herein is a method for reducing the time-dependent decline in plasma concentration of Compound (I), the method comprising administering to a subject (a) Compound (I) and (b) a CYP3A4 inhibitor.

[0040] Further disclosed herein is a combination therapy comprising (a) Compound (I) and (b) a CYP3A4 inhibitor for use in attenuating the time-dependent decline in plasma concentrations of Compound (I).

[0041] Further disclosed herein is the use of (a) Compound (I), and (b) a CYP3A4 inhibitor in the manufacture of a medicament for reducing the time-dependent decline in plasma concentration of Compound (I).

[0042] Disclosed herein is a method of increasing wakefulness in a subject in need thereof, comprising administering to the subject: (a) Compound (I); and (b) an agent for decreasing the metabolism of Compound (I).

[0043] Further disclosed herein is a combination therapy for use in increasing wakefulness in a subject, the combination therapy comprising: (a) Compound (I); and (b) an agent for decreasing the metabolism of Compound (I).

[0044] Further disclosed herein is the use of (a) methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate (Compound (I)), or a salt thereof, and (b) an agent for decreasing the metabolism of Compound (I), in the manufacture of a medicament for increasing wakefulness.

[0045] Disclosed herein is a method for reducing excessive sleepiness in a subject in need thereof, comprising administering to the subject: (a) Compound (I); and (b) an agent for decreasing the metabolism of Compound (I).

[0046] Further disclosed herein is a combination therapy for use in reducing excessive sleepiness in a subject, the combination therapy comprising (a) Compound (I) and (b) an agent for decreasing the metabolism of Compound (I).

[0047] Further disclosed herein is the use of (a) Compound (I), and (b) an agent for decreasing the metabolism of Compound (I), in the manufacture of a medicament for reducing excessive sleepiness in a subject.

[0048] Disclosed herein is a method for treating excessive sleepiness in a subject in need thereof, comprising administering to the subject (a) Compound (I) and (b) an agent for decreasing the metabolism of Compound (I).

[0049] Further disclosed herein is a combination therapy for use in treating excessive sleepiness in a subject, the combination therapy including (a) Compound (I) and (b) an agent for decreasing the metabolism of Compound (I).

[0050] Further disclosed herein is the use of (a) Compound (I), and (b) an agent for decreasing the metabolism of Compound (I), in the manufacture of a medicament for treating excessive sleepiness.

[0051] Disclosed herein is a method of treating narcolepsy type 1 in a subject in need thereof, comprising administering to the subject: (a) Compound (I); and (b) an agent for decreasing the metabolism of Compound (I).

[0052] Further disclosed herein is a combination therapy for use in treating narcolepsy type 1 in a subject in need thereof, comprising: (a) Compound (I); and (b) an agent for decreasing the metabolism of Compound (I).

[0053] Disclosed herein is the use of (a) Compound (I), and (b) an agent for decreasing the metabolism of Compound (I), in the manufacture of a medicament for treating narcolepsy type 1 in a subject in need thereof.

[0054] Alternatively, disclosed herein are methods for alleviating cataplexy-like events (e.g., cataplexy) in a subject in need thereof, comprising administering to the subject (a) Compound (I) and (b) an agent for reducing the metabolism of Compound (I). In some embodiments, the subject is suffering from or has been diagnosed with narcolepsy type 1. In some embodiments, the cataplexy-like events are cataplexy.

[0055] Further disclosed herein is a combination therapy comprising (a) Compound (I) and (b) an agent for reducing the metabolism of Compound (I) for use in alleviating cataplexy-like events (e.g., cataplexy) in a subject in need thereof. In some embodiments, the subject is suffering from or has been diagnosed with narcolepsy type 1. In some embodiments, the cataplexy-like event is cataplexy.

[0056] Disclosed herein is the use of (a) Compound (I) and (b) an agent for reducing the metabolism of Compound (I) in the manufacture of a medicament for alleviating a cataplexy-like event (e.g., cataplexy) in a subject in need thereof. In some embodiments, the subject is suffering from or has been diagnosed with narcolepsy type 1. In some embodiments, the cataplexy-like event is cataplexy.

[0057] Disclosed herein is a method for treating shift work disorder, shift work sleep disorder, or jet lag syndrome in a subject in need thereof, comprising administering to the subject (a) Compound (I), and (b) an agent for decreasing the metabolism of Compound (I).

[0058] Further disclosed herein is a combination therapy comprising (a) Compound (I), and (b) an agent for decreasing the metabolism of Compound (I), for use in treating shift work disorder, shift work sleep disorder, or jet lag syndrome in a subject in need thereof.

[0059] Disclosed herein is the use of (a) Compound (I); and (b) an agent for decreasing the metabolism of Compound (I) in the manufacture of a medicament for treating shift work disorder, shift work sleep disorder, or jet lag syndrome in a subject in need thereof.

[0060] Disclosed herein is a method for improving the pharmacokinetics of an orexin type 2 receptor (OX2R) agonist, the method comprising administering to a subject (a) an orexin type 2 receptor (OX2R) agonist and (b) an agent for decreasing the metabolism of the OX2R agonist.

[0061] Further disclosed herein is a combination therapy for use in improving the pharmacokinetics of an orexin type 2 receptor (OX2R) agonist, comprising: (a) an OX2R agonist; and (b) an agent for decreasing the metabolism of the OX2R agonist.

[0062] Further disclosed herein is the use of (a) an orexin type 2 receptor (OX2R) agonist, and (b) an agent for decreasing the metabolism of the OX2R agonist, in the manufacture of a medicament for improving the pharmacokinetics of the OX2R agonist.

[0063] Further disclosed herein is an agent for decreasing the metabolism of an OX2R agonist for use in improving the pharmacokinetics of an OX2R agonist.

[0064] Further disclosed herein is the use of an agent for decreasing the metabolism of an OX2R agonist in the manufacture of a medicament for improving the pharmacokinetics of an OX2R agonist.

[0065] Disclosed herein is a method for increasing the plasma concentration of an orexin type 2 receptor (OX2R) agonist, the method comprising administering to a subject (a) an orexin type 2 receptor (OX2R) agonist and (b) an agent for decreasing the metabolism of the OX2R agonist.

[0066] Further disclosed herein is a combination therapy for use in increasing the plasma concentration of an orexin type 2 receptor (OX2R) agonist, comprising: (a) an OX2R agonist; and (b) an agent for decreasing the metabolism of the OX2R agonist.

[0067] Further disclosed herein is the use of (a) an orexin type 2 receptor (OX2R) agonist, and (b) an agent for decreasing the metabolism of the OX2R agonist, in the manufacture of a medicament for increasing the plasma concentration of the OX2R agonist.

[0068] Further disclosed herein is an agent for decreasing the metabolism of an OX2R agonist for use in increasing the plasma concentration of the OX2R agonist.

[0069] Further disclosed herein is the use of an agent for decreasing the metabolism of an OX2R agonist in the manufacture of a medicament for increasing the plasma concentration of an OX2R agonist.

[0070] Disclosed herein is a method for maintaining the pharmacological effect of an orexin type 2 receptor (OX2R) agonist, the method comprising administering to a subject (a) an orexin type 2 receptor (OX2R) agonist, and (b) an agent for decreasing the metabolism of the OX2R agonist.

[0071] Further disclosed herein is a combination therapy for use in maintaining the pharmacological effect of an orexin type 2 receptor (OX2R) agonist, comprising (a) an OX2R agonist and (b) an agent for decreasing the metabolism of the OX2R agonist.

[0072] Further disclosed herein is the use of (a) an orexin type 2 receptor (OX2R) agonist, and (b) an agent for reducing the metabolism of the OX2R agonist, in the manufacture of a medicament for maintaining the pharmacological action of the OX2R agonist.

[0073] Disclosed herein is a method for maintaining a pharmaceutically effective plasma concentration of an orexin type 2 receptor (OX2R) agonist, the method comprising administering to a subject (a) an orexin type 2 receptor (OX2R) agonist, and (b) an agent for decreasing the metabolism of the OX2R agonist.

[0074] Further disclosed herein is a combination therapy for use in maintaining a pharmaceutically effective plasma concentration of an orexin type 2 receptor (OX2R) agonist, comprising: (a) an OX2R agonist; and (b) an agent for decreasing the metabolism of the OX2R agonist.

[0075] Further disclosed herein is the use of (a) an orexin type 2 receptor (OX2R) agonist, and (b) an agent for reducing the metabolism of the OX2R agonist, in the manufacture of a medicament for maintaining a pharmaceutically effective plasma concentration of the OX2R agonist.

[0076] Disclosed herein is a method for decreasing the metabolism of an orexin type 2 receptor (OX2R) agonist, the method comprising administering to a subject (a) an orexin type 2 receptor (OX2R) agonist and (b) a CYP3A4 inhibitor.

[0077] Further disclosed herein is a combination therapy comprising (a) an orexin 2 receptor (OX2R) agonist and (b) a CYP3A4 inhibitor for use in decreasing the metabolism of the OX2R agonist.

[0078] Further disclosed herein is the use of (a) an orexin 2 receptor (OX2R) agonist and (b) a CYP3A4 inhibitor in the manufacture of a medicament for decreasing the metabolism of the OX2R agonist.

[0079] Disclosed herein is a method for attenuating the time-dependent decline in plasma concentration of an orexin type 2 receptor (OX2R) agonist, the method comprising administering to a subject (a) an orexin type 2 receptor (OX2R) agonist and (b) a CYP3A4 inhibitor.

[0080] Further disclosed herein is a combination therapy comprising (a) an orexin type 2 receptor (OX2R) agonist and (b) a CYP3A4 inhibitor for use in attenuating the time-dependent decline in plasma concentration of the OX2R agonist.

[0081] Further disclosed herein is the use of (a) an orexin 2 receptor (OX2R) agonist and (b) a CYP3A4 inhibitor in the manufacture of a medicament for attenuating the time-dependent decline in plasma concentration of an OX2R agonist.

[0082] Disclosed herein is a method of increasing wakefulness in a subject in need thereof, the method comprising administering to the subject (a) an orexin type 2 receptor (OX2R) agonist and (b) an agent for decreasing the metabolism of the OX2R agonist.

[0083] Further disclosed herein is a combination therapy for use in increasing wakefulness in a subject, the combination therapy comprising (a) an orexin 2 receptor (OX2R) agonist and (b) an agent for decreasing the metabolism of the OX2R agonist.

[0084] Further disclosed herein is the use of (a) an orexin type 2 receptor (OX2R) agonist and (b) an agent for decreasing the metabolism of the OX2R agonist in the manufacture of a medicament for increasing wakefulness.

[0085] Disclosed herein is a method for reducing excessive sleepiness in a subject in need thereof, the method comprising administering to the subject (a) an orexin type 2 receptor (OX2R) agonist and (b) an agent for decreasing the metabolism of the OX2R agonist.

[0086] Further disclosed herein is a combination therapy comprising (a) an orexin 2 receptor (OX2R) agonist and (b) an agent for decreasing the metabolism of the OX2R agonist, for use in reducing excessive sleepiness in a subject.

[0087] Further disclosed herein is the use of (a) an orexin type 2 receptor (OX2R) agonist, and (b) an agent for decreasing the metabolism of the OX2R agonist, in the manufacture of a medicament for reducing excessive sleepiness in a subject.

[0088] Disclosed herein is a method for treating excessive sleepiness in a subject in need thereof, comprising administering to the subject (a) an orexin type 2 receptor (OX2R) agonist and (b) an agent for decreasing the metabolism of the OX2R agonist.

[0089] Further disclosed herein is a combination therapy for use in treating excessive sleepiness in a subject, the combination therapy including (a) an orexin 2 receptor (OX2R) agonist and (b) an agent for decreasing the metabolism of the OX2R agonist.

[0090] Further disclosed herein is the use of (a) an orexin type 2 receptor (OX2R) agonist and (b) an agent for decreasing the metabolism of the OX2R agonist in the manufacture of a medicament for treating excessive sleepiness.

[0091] Disclosed herein is a method of treating narcolepsy type 1 in a subject in need thereof, comprising administering to the subject (a) an orexin type 2 receptor (OX2R) agonist and (b) an agent for decreasing the metabolism of the OX2R agonist.

[0092] Further disclosed herein is a combination therapy comprising (a) an orexin 2 receptor (OX2R) agonist and (b) an agent for decreasing the metabolism of the OX2R agonist for use in treating narcolepsy type 1 in a subject in need thereof.

[0093] Disclosed herein is the use of (a) an orexin type 2 receptor (OX2R) agonist, and (b) an agent for reducing the metabolism of the OX2R agonist, in the manufacture of a medicament for treating narcolepsy type 1 in a subject in need thereof.

[0094] Alternatively, disclosed herein are methods for alleviating cataplexy-like events (e.g., cataplexy) in a subject in need thereof, comprising administering to the subject (a) an orexin 2 receptor (OX2R) agonist and (b) an agent for reducing the metabolism of the OX2R agonist. In some embodiments, the subject is suffering from or has been diagnosed with narcolepsy type 1. In some embodiments, the cataplexy-like events are cataplexy.

[0095] Further disclosed herein is a combination therapy comprising (a) an orexin 2 receptor (OX2R) agonist and (b) an agent for reducing the metabolism of the OX2R agonist for use in reducing cataplexy-like events (e.g., cataplexy) in a subject in need thereof. In some embodiments, the subject is suffering from or diagnosed with narcolepsy type 1. In some embodiments, the cataplexy-like event is cataplexy.

[0096] Disclosed herein is the use of (a) an orexin 2 receptor (OX2R) agonist and (b) an agent for reducing the metabolism of the OX2R agonist in the manufacture of a medicament for alleviating cataplexy-like events (e.g., cataplexy) in a subject in need thereof. In some embodiments, the subject is suffering from or diagnosed with narcolepsy type 1. In some embodiments, the cataplexy-like event is cataplexy.

[0097] Disclosed herein is a method for treating shift work disorder, shift work sleep disorder, or jet lag syndrome in a subject in need thereof, the method comprising administering to the subject (a) an orexin type 2 receptor (OX2R) agonist, and (b) an agent for decreasing the metabolism of the OX2R agonist.

[0098] Further disclosed herein is a combination therapy comprising (a) an orexin 2 receptor (OX2R) agonist and (b) an agent for decreasing the metabolism of the OX2R agonist, for use in treating shift work disorder, shift work sleep disorder, or jet lag syndrome in a subject in need thereof.

[0099] Disclosed herein is the use of (a) an orexin type 2 receptor (OX2R) agonist, and (b) an agent for decreasing the metabolism of the OX2R agonist, in the manufacture of a medicament for treating shift work disorder, shift work sleep disorder, or jet lag syndrome in a subject in need thereof.

[0100] In some embodiments, the OX2R agonist is compound (I).

[0101] The methods and uses disclosed herein may be for treating narcolepsy type 1 in a subject in need thereof. In some embodiments, treating narcolepsy type 1 may include reducing or alleviating one or more symptoms of narcolepsy type 1. The one or more symptoms of narcolepsy type 1 may be selected from excessive daytime sleepiness (EDS) and cataplexy. In some embodiments, the one or more symptoms of narcolepsy type 1 may be selected from excessive daytime sleepiness (EDS) and cataplexy. Narcolepsy may be diagnosed according to diagnostic criteria commonly used in the field, such as the International Classification of Sleep Disorders, Third Edition (ICSD-3) and the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).

[0102] The methods and uses disclosed herein may increase wakefulness and / or reduce and / or treat excessive sleepiness in a subject in need thereof. In some embodiments, the wakefulness and / or reduction and / or treatment of excessive sleepiness is determined by electroencephalography (EEG) and / or electromyography (EMG). In some embodiments, the wakefulness and / or reduction of sleepiness is determined by using the Maintenance of Wakefulness Test (MWT). The MWT can be quantified by EEG. The EEG is a test that detects electrical activity in the brain using small metal discs or electrodes attached to the scalp. In some embodiments, the wakefulness and / or reduction of sleepiness is determined by using the Repeated Sleep Latency Test (MSLT) or the Oxford Sleep Resistance (OSLER) test. In some embodiments, the test is the Karolinska Sleepiness Scale (KSS), the Epworth Sleepiness Scale (ESS), or the Stanford Sleepiness Scale. In some embodiments, the subject with excessive sleepiness is a patient with narcolepsy type 1, narcolepsy type 2, idiopathic hypersomnia, hypersomnia, hypersomnolence, sleep apnea syndrome (e.g., obstructive sleep apnea, obstructive sleep apnea due to the use of continuous positive airway pressure); or a disorder of consciousness, such as coma; or a narcolepsy syndrome with narcoleptic symptoms; a hypersomnolence or hypersomnia syndrome with excessive daytime sleepiness (e.g., Parkinson's disease, Guillain-Barré syndrome, and Kleine-Levin syndrome); Parkinson's disease, Alzheimer's disease, DLB The patient may suffer from or be diagnosed with: (dementia with Lewy bodies), Prader-Willi syndrome, depression (depression, atypical depression, major depressive disorder, treatment-resistant depression), attention deficit hyperactivity disorder (ADHD), excessive daytime sleepiness in sleep apnea (e.g., obstructive sleep apnea, obstructive sleep apnea with continuous positive airway pressure) or other insomnia disorder; or residual excessive daytime sleepiness in sleep apnea (e.g., obstructive sleep apnea, obstructive sleep apnea with continuous positive airway pressure).In some embodiments, the subject's excessive sleepiness may be caused by or associated with narcolepsy type 1, narcolepsy type 2, idiopathic hypersomnia, hypersomnolence, hypersomnolence, sleep apnea (e.g., obstructive sleep apnea, obstructive sleep apnea due to the use of continuous positive airway pressure); or a disturbance in consciousness, such as coma; or narcolepsy with narcoleptic symptoms; hypersomnolence or hypersomnia with excessive daytime sleepiness (e.g., Parkinson's disease, Guillain-Barré syndrome, and Kleine-Levin syndrome), Parkinson's disease, Alzheimer's disease, DLB (dementia with Lewy bodies), Prader-Willi syndrome, depression (depression, atypical depression, major depressive disorder, treatment-resistant depression), ADHD, sleep apnea (e.g., obstructive sleep apnea, obstructive sleep apnea due to the use of continuous positive airway pressure), or other insomnia disorders.

[0103] The methods and uses disclosed herein can increase wakefulness and / or reduce and / or treat excessive sleepiness in a subject in need thereof. In some embodiments, the excessive sleepiness is excessive daytime sleepiness.

[0104] The methods and uses disclosed herein may increase the plasma concentration of Compound (I) in a subject, or may maintain a pharmaceutically effective plasma concentration of Compound (I) in a subject, or may reduce the time-dependent decrease in the plasma concentration of Compound (I) in a subject. In some embodiments, the plasma concentration of Compound (I) is increased by at least 5-fold, 10-fold, 25-fold, 50-fold, 100-fold, 200-fold, 500-fold, 1000-fold, or more by administering Compound (I) and an agent to reduce the metabolism of Compound (I), wherein the increase is compared to the plasma concentration of Compound (I) resulting from administration of Compound (I) alone. In some embodiments, the plasma concentration of Compound (I) in a subject may be measured at least 4, 6, 9, 12, 24, 36, or 48 hours or more after administration of Compound (I) to the subject.

[0105] The methods and uses disclosed herein can maintain a pharmaceutically effective plasma concentration of Compound (I) in a subject. In some embodiments, the pharmaceutically effective plasma concentration of Compound (I) can be at least 5, 10, 25, 50, 75, 100, 150, 200, 250, or 300 ng / mL, or can be higher. In some embodiments, the pharmaceutically effective plasma concentration of Compound (I) in a subject can be measured at least 4, 6, 9, 12, 24, 36, or 48 hours or more after administration of Compound (I) to the subject.

[0106] The methods and uses disclosed herein may increase the Cmax of Compound (I) in a subject. In some embodiments, the Cmax of Compound (I) is increased by at least 5-fold, 10-fold, 25-fold, 50-fold, 100-fold, 200-fold, or more by administering Compound (I) and an agent to reduce the metabolism of Compound (I), wherein the increase is compared to the Cmax of Compound (I) by administering Compound (I) alone.

[0107] The methods and uses disclosed herein may increase the AUC of Compound (I) in a subject. In some embodiments, the AUC of Compound (I) is increased by at least 5-fold, 10-fold, 25-fold, 50-fold, 100-fold, 200-fold, 500-fold, or more by administering Compound (I) and an agent to reduce the metabolism of Compound (I), wherein the increase is compared to the AUC of Compound (I) by administering Compound (I) alone.

[0108] The methods and uses disclosed herein may increase the AUC of Compound (I) in a subject. In some embodiments, the AUC of Compound (I) is increased by at least 5-fold, 10-fold, 25-fold, 50-fold, 100-fold, 200-fold, 500-fold, or more by administering Compound (I) and an agent to reduce the metabolism of Compound (I), wherein the increase is compared to the AUC of Compound (I) by administering Compound (I) alone.

[0109] AUClast and AUCinf can be calculated as follows: AUClast: area under the concentration-time curve from time 0 to the last quantifiable concentration calculated by the linear-logarithmic trapezoidal method. AUCinf: area under the concentration-time curve from time 0 extrapolated to infinity. AUC ∞ The ratio of the final measurable blood concentration to the elimination rate constant is called the AUC last It is calculated as the sum of

[0110] The methods and uses disclosed herein may reduce cataplexy-like events (e.g., cataplexy) in a subject in need thereof. In some embodiments, the number of cataplexy-like events is reduced by 1 to 20 or more cataplexy-like events. In some embodiments, the number of cataplexy-like events is reduced by 1 to 8 or more cataplexy-like events in a 24-hour period. In some embodiments, the number of cataplexy-like events is reduced by 50% to 95% or more cataplexy-like events compared to a subject not administered Compound (I). In some embodiments, the number of cataplexy-like events is reduced by 1 to 20 or more events in a 1 to 15 day period. Cataplexy-like events include cataplexy.

[0111] The methods and uses disclosed herein are useful in treating narcolepsy type 1, narcolepsy type 2, idiopathic hypersomnia, hypersomnolence, hypersomnolence, sleep apnea syndrome (e.g., obstructive sleep apnea, obstructive sleep apnea caused by the use of continuous positive airway pressure), and narcolepsy syndromes with disturbances of consciousness, such as coma, and narcolepsy-like symptoms, hypersomnolence or hypersomnia syndromes with excessive daytime sleepiness (e.g., Parkinson's disease, Guillain-Barré syndrome, and Kleine-Levin syndrome), Parkinson's disease, Alzheimer's disease, DLB ( The present invention may treat a disease selected from dementia with Lewy bodies, Prader-Willi syndrome, depression (depression, atypical depression, major depressive disorder, treatment-resistant depression), ADHD, excessive daytime sleepiness in sleep apnea syndrome (e.g., obstructive sleep apnea, obstructive sleep apnea with continuous positive airway pressure), residual excessive daytime sleepiness in sleep apnea syndrome (e.g., obstructive sleep apnea, obstructive sleep apnea with continuous positive airway pressure), as well as other insomnia disorders, obesity, diabetes, etc.

[0112] The methods and uses disclosed herein may comprise carrying out one or more tests to quantify the sleepiness of a subject. In some embodiments, the test is selected from MSLT, MWT and OSLER test. In some embodiments, the test is MWT. In some embodiments, the test is KSS, ESS or Stanford Sleepiness Scale.

[0113] The methods and uses disclosed herein include administering Compound (I) to a subject in need thereof. In some embodiments, Compound (I) is administered orally. In some embodiments, Compound (I) is administered parenterally. In some embodiments, parenteral administration is intravenous, subcutaneous, transdermal, intradermal, or transmucosal administration.

[0114] Compound (I) may be administered orally and parenterally, for example, by intramuscular, intraperitoneal, intravenous, intraarterial, intracerebroventricular, intracisternal injection or infusion, subcutaneous injection; or implantation; or by inhalation spray, intratracheal, intranasal, intravaginal, intrarectal, subdermal, transdermal, intradermal, epidural, intraocular insert, or eye drops, in suitable unit dosage forms containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants, and vehicles appropriate for each administration route.

[0115] Alternatively, or in addition, administering Compound (I) may comprise administering an effective amount of Compound (I). In some embodiments, administering Compound (I) may comprise administering a therapeutically effective amount of Compound (I). The effective amount of Compound (I) may be about 3 mg to about 500 mg. The effective amount of Compound (I) may be about 3 mg to about 400 mg. The effective amount of Compound (I) may be about 3 mg to about 300 mg. The effective amount of Compound (I) may be about 3 mg to about 200 mg. The effective amount of Compound (I) may be about 3 mg to 100 mg. The effective amount of Compound (I) may be about 3 mg to 50 mg. In some embodiments, the effective amount and the therapeutically effective amount are the same. The effective amount of Compound (I) may be 5 to 300 mg. The effective amount of Compound (I) may be 5 to 250 mg. The effective amount of Compound (I) may be 5 to 200 mg. The effective amount of Compound (I) may be 5 to 150 mg. The effective amount of Compound (I) may be 5 to 100 mg. The effective amount of Compound (I) or a salt thereof may be 5 to 50 mg. The effective amount of Compound (I) may be 10 to 300 mg. The effective amount of Compound (I) may be 10 to 250 mg. The effective amount of Compound (I) may be 10 to 200 mg. The effective amount of Compound (I) may be 10 to 150 mg. The effective amount of Compound (I) may be 10 to 100 mg. The effective amount of Compound (I) may be 10 to 50 mg. In some embodiments, the effective amount and the therapeutically effective amount are the same.

[0116] Compound (I) may be administered one to three times daily, or more frequently. In some embodiments, Compound (I) is administered at least once daily. In some embodiments, Compound (I) is administered at least twice daily.

[0117] Compound (I) may be administered 1 to 7 times per week, or more frequently. In some embodiments, Compound (I) is administered once per week. In some embodiments, Compound (I) is administered at least twice per week. In some embodiments, Compound (I) is administered at least three times per week.

[0118] The compositions, methods, and uses disclosed herein may include an agent for reducing the metabolism of an OX2R agonist. The agent for reducing the metabolism of an OX2R agonist may increase the bioavailability or systemic exposure of the OX2R agonist. The agent for reducing the metabolism of an OX2R agonist may reduce the first-pass metabolism or systemic clearance of the OX2R agonist. The agent for reducing the metabolism of an OX2R agonist may improve the pharmacokinetics of the OX2R agonist. The agent for reducing the metabolism of an OX2R agonist may increase the plasma concentration of the OX2R agonist. In some embodiments, the OX2R agonist is Compound (I). In some embodiments, Compound (I) is (2R,3S)-3-((methylsulfonyl)amino)-2-(((cis-4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate methyl (hereinafter "Compound A") or a salt thereof. In some embodiments, the agent for reducing the metabolism of the OX2R agonist is an inhibitor of one or more enzymes of the cytochrome P450 enzyme system. In some embodiments, the agent for reducing the metabolism of the OX2R agonist is a CYP3A inhibitor. In some embodiments, the agent for reducing the metabolism of the OX2R agonist is a CYP3A4 inhibitor. In some embodiments, the CYP3A4 inhibitor is selected from the group consisting of atazanavir, boceprevir, clarithromycin, cobicistat, conivaptan, curcumin, danazol, danoprevir, darunavir, delavirdine, diltiazem, dithiocarb, econazole, efavirenz, elvitegravir, ergotamine, idelalisib, indinavir, itraconazole, ketoconazole, loperamide, lopinavir, methimazole, midostaurin, naloxone, nefazodone, nelfinavir, nilotinib, posaconazole, ribociclib, ritonavir, saquinavir, stiripentol, telaprevir, telithromycin, terfenadine, tipranavir, troleandomycin, and voriconazole. In some embodiments, the CYP3A4 inhibitor is selected from the group consisting of ritonavir and cobicistat, hi some embodiments, the CYP3A4 inhibitor is cobicistat.

[0119] The agent for reducing the metabolism of OX2R agonists can be administered simultaneously with Compound (I).The agent for reducing the metabolism of OX2R agonists can be administered after the administration of the OX2R agonist.The agent for reducing the metabolism of OX2R agonists can be administered before the administration of the OX2R agonist.In some embodiments, the agent for reducing the metabolism of OX2R agonists is administered daily (single daily dose or multiple daily doses).In some embodiments, the agent for reducing the metabolism of OX2R agonists is administered once a day.In some embodiments, the agent for reducing the metabolism of OX2R agonists is administered at least twice a day.

[0120] The agent for reducing the metabolism of OX2R agonists can be administered orally and parenterally, for example, by intramuscular, intraperitoneal, intravenous, intraarterial, intracerebroventricular, intracisternal injection or infusion, subcutaneous injection, or implantation, in a suitable unit dosage form containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants, and vehicles suitable for each administration route; or by inhalation spray, intratracheal, intranasal, intravaginal, intrarectal, subdermal, transdermal, intradermal, epidural, intraocular insert, or eye drops. The agent for reducing the metabolism of OX2R agonists can be administered orally.

[0121] The agent for reducing the metabolism of an OX2R agonist can be formulated together with the OX2R agonist. The agent for reducing the metabolism of an OX2R agonist can be formulated separately from the OX2R agonist. The composition or combination therapy disclosed herein can include a single container containing an OX2R agonist and an agent for reducing the metabolism of an OX2R agonist. Alternatively, the composition or combination therapy disclosed herein can include a first container containing an OX2R agonist and a second container containing an agent for reducing the metabolism of an OX2R agonist.

[0122] The agent for reducing the metabolism of an OX2R agonist can be administered 1 to 3 times a day, or more frequently. In some embodiments, the agent for reducing the metabolism of an OX2R agonist is administered at least once a day. In some embodiments, the agent for reducing the metabolism of an OX2R agonist is administered at least twice a day.

[0123] The agent for reducing the metabolism of an OX2R agonist may be administered 1 to 7 times per week, or more frequently. In some embodiments, the agent for reducing the metabolism of an OX2R agonist is administered once per week. In some embodiments, the agent for reducing the metabolism of an OX2R agonist is administered at least twice per week. In some embodiments, the agent for reducing the metabolism of an OX2R agonist is administered at least three times per week.

[0124] The agent for decreasing the metabolism of an OX2R agonist can be cobicistat. Administering cobicistat can include administering an effective amount of cobicistat. In some embodiments, administering cobicistat can include administering a therapeutically effective amount of cobicistat. An effective amount of cobicistat can be 5 mg to 500 mg, 10 mg to 400 mg, 50 mg to 300 mg, 75 mg to 250 mg, or 100 mg to 200 mg. In some embodiments, an effective amount of cobicistat can be 150 mg.

[0125] The agent for reducing the metabolism of an OX2R agonist can be ritonavir. Administering ritonavir can include administering an effective amount of ritonavir. In some embodiments, administering ritonavir can include administering a therapeutically effective amount of ritonavir. The effective amount of ritonavir can be 5 mg to 500 mg, 10 mg to 400 mg, 15 mg to 300 mg, 20 mg to 200 mg, or 25 mg to 100 mg. In some embodiments, the effective amount of ritonavir can be 25 mg, 50 mg, or 100 mg.

[0126] The compositions, methods, and uses disclosed herein may include an agent for decreasing the metabolism of Compound (I). An agent for decreasing the metabolism of Compound (I) may increase the bioavailability or systemic exposure of Compound (I). An agent for decreasing the metabolism of Compound (I) may decrease the first-pass metabolism or systemic clearance of Compound (I). An agent for decreasing the metabolism of Compound (I) may improve the pharmacokinetics of Compound (I). An agent for decreasing the metabolism of Compound (I) may increase the plasma concentration of Compound (I). In some embodiments, an agent for decreasing the metabolism of Compound (I) is an inhibitor of one or more enzymes of the cytochrome P450 enzyme system. In some embodiments, an agent for decreasing the metabolism of Compound (I) is a CYP3A inhibitor. In some embodiments, an agent for decreasing the metabolism of Compound (I) is a CYP3A4 inhibitor. In some embodiments, the CYP3A4 inhibitor is selected from the group consisting of atazanavir, boceprevir, clarithromycin, cobicistat, conivaptan, curcumin, danazol, danoprevir, darunavir, delavirdine, diltiazem, dithiocarb, econazole, efavirenz, elvitegravir, ergotamine, idelalisib, indinavir, itraconazole, ketoconazole, loperamide, lopinavir, methimazole, midostaurin, naloxone, nefazodone, nelfinavir, nilotinib, posaconazole, ribociclib, ritonavir, saquinavir, stiripentol, telaprevir, telithromycin, terfenadine, tipranavir, troleandomycin, and voriconazole. In some embodiments, the CYP3A4 inhibitor is selected from the group consisting of ritonavir and cobicistat, hi some embodiments, the CYP3A4 inhibitor is cobicistat.

[0127] The agent for reducing the metabolism of Compound (I) may be administered simultaneously with Compound (I). The agent for reducing the metabolism of Compound (I) may be administered after administration of Compound (I). The agent for reducing the metabolism of Compound (I) may be administered before administration of Compound (I). In some embodiments, the agent for reducing the metabolism of Compound (I) is administered daily (single daily dose or multiple daily doses). In some embodiments, the agent for reducing the metabolism of Compound (I) is administered once daily. In some embodiments, the agent for reducing the metabolism of Compound (I) is administered at least twice daily.

[0128] The agent for reducing the metabolism of compound (I) can be administered orally and parenterally, for example, by intramuscular, intraperitoneal, intravenous, intraarterial, intracerebroventricular, intracisternal injection or infusion, subcutaneous injection, or implantation, in a suitable unit dosage form containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants, and vehicles suitable for each administration route. The agent for reducing the metabolism of compound (I) can be administered orally, for example, by intramuscular, intraperitoneal, intravenous, intraarterial, intracerebroventricular, intracisternal injection or infusion, subcutaneous injection, or implantation, or by inhalation spray, intratracheal, intranasal, intravaginal, intrarectal, subdermal, transdermal, intradermal, epidural, intraocular insert, or eye drops. The agent for reducing the metabolism of compound (I) can be administered orally.

[0129] The agent for reducing the metabolism of Compound (I) may be formulated together with Compound (I). The agent for reducing the metabolism of Compound (I) may be formulated separately from Compound (I). The compositions or combination therapies disclosed herein may comprise a single container containing Compound (I) and an agent for reducing the metabolism of Compound (I). Alternatively, the compositions or combination therapies disclosed herein may comprise a first container containing Compound (I) and a second container containing an agent for reducing the metabolism of Compound (I).

[0130] The agent for reducing the metabolism of Compound (I) may be administered one to three times daily, or more frequently. In some embodiments, the agent for reducing the metabolism of Compound (I) is administered at least once daily. In some embodiments, the agent for reducing the metabolism of Compound (I) is administered at least twice daily.

[0131] The agent for reducing the metabolism of Compound (I) may be administered 1 to 7 times per week, or more frequently. In some embodiments, the agent for reducing the metabolism of Compound (I) is administered once per week. In some embodiments, the agent for reducing the metabolism of Compound (I) is administered at least twice per week. In some embodiments, the agent for reducing the metabolism of Compound (I) is administered at least three times per week.

[0132] The agent for decreasing the metabolism of Compound (I) can be cobicistat. Administering cobicistat can include administering an effective amount of cobicistat. In some embodiments, administering cobicistat can include administering a therapeutically effective amount of cobicistat. An effective amount of cobicistat can be 5 mg to 500 mg, 10 mg to 400 mg, 50 mg to 300 mg, 75 mg to 250 mg, or 100 mg to 200 mg. In some embodiments, an effective amount of cobicistat can be 150 mg.

[0133] The agent for reducing the metabolism of Compound (I) can be ritonavir. Administering ritonavir can include administering an effective amount of ritonavir. In some embodiments, administering ritonavir can include administering a therapeutically effective amount of ritonavir. The effective amount of ritonavir can be 5 mg to 500 mg, 10 mg to 400 mg, 15 mg to 300 mg, 20 mg to 200 mg, or 25 mg to 100 mg. In some embodiments, the effective amount of ritonavir can be 25 mg, 50 mg, or 100 mg.

[0134] The methods disclosed herein may further include administering one or more additional therapies. The kits and compositions disclosed herein may further include one or more additional therapies. The one or more additional therapies may be selected from stimulants, antidepressants, central nervous system depressants, histamine 3 (H3) receptor antagonists, and any other combination medications described herein. In some embodiments, the stimulant is modafinil. In some embodiments, the antidepressant is clomipramine. In some embodiments, the central nervous system depressant is sodium oxybate. In some embodiments, the H3 receptor antagonist is pitolisant.

[0135] Two or more of the above-mentioned combination drugs may be used in a mixture in an appropriate ratio.

[0136] The methods disclosed herein may not further comprise administering one or more additional agents for reducing the metabolism of Compound (I). The kits and compositions disclosed herein may not further comprise one or more additional agents for reducing the metabolism of Compound (I).

[0137] Further disclosed herein is a pharmaceutical composition comprising: (a) methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate (Compound (I)) or a salt thereof; (b) an agent for decreasing the metabolism of Compound (I); and (c) a pharmaceutically acceptable carrier therefor.

[0138] Further disclosed herein is a pharmaceutical composition comprising (a) an OX2R agonist, (b) an agent for decreasing the metabolism of the OX2R agonist, and (c) a pharmaceutically acceptable carrier therefor.

[0139] The pharmaceutically acceptable carrier may be a cyclodextrin. The cyclodextrin may be betadex sulfobutylether sodium.

[0140] In some embodiments, various organic or inorganic carrier substances commonly used as formulation materials are used as pharmaceutically acceptable carriers. These may be incorporated as excipients, lubricants, binders, and disintegrants for solid formulations; or solvents, solubilizers, suspending agents, isotonicity adjusting agents, buffers, and demulcents for liquid formulations; and the like, and formulation additives such as preservatives, antioxidants, coloring agents, sweeteners, and the like may be added as needed.

[0141] Examples of dosage forms of the pharmaceutical composition include tablets (including sugar-coated tablets, film-coated tablets, and orally disintegrating tablets), capsules (including soft capsules and microcapsules), granules, powders, lozenges, syrups, emulsions, suspensions, films (e.g., orally disintegrating films), injections (e.g., subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections, and infusions), topical preparations (e.g., dermatological preparations, ointments), suppositories (e.g., rectal suppositories, vaginal suppositories), pellets, nasal preparations, pulmonary preparations (inhalants), and eye drops, each of which can be safely administered orally or parenterally (e.g., topically, rectally, or intravenously). These preparations can also be controlled-release preparations (e.g., sustained-release microcapsules), e.g., immediate-release preparations, sustained-release preparations, and the like.

[0142] In some embodiments, the pharmaceutical composition is formulated for oral administration. In some embodiments, the pharmaceutical composition is formulated for parenteral administration. In some embodiments, the pharmaceutical composition is formulated for intravenous, subcutaneous, transdermal, intradermal, or transmucosal administration. In some embodiments, the pharmaceutical composition is formulated for intravenous administration. In some embodiments, the pharmaceutical composition is formulated for subcutaneous administration. In some embodiments, the pharmaceutical composition is formulated for transdermal administration.

[0143] In some embodiments, the OX2R agonist is Compound (I). In some embodiments, Compound (I) is an optically active compound. In some embodiments, Compound (I) is methyl (2R,3S)-3-((methylsulfonyl)amino)-2-(((cis-4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate (Compound A). Compound (I), including its optically active compounds, can be prepared as disclosed in WO2017 / 135306, the entire contents of which are incorporated herein by reference.

[0144] Further disclosed herein are kits comprising Compound (I). In some embodiments, the kit comprises (a) a container comprising Compound (I), (b) a container comprising an agent for reducing the metabolism of Compound (I), and (c) instructions for administering Compound (I) and the agent.

[0145] Further disclosed herein is a kit comprising an OX2R agonist. In some embodiments, the kit comprises: (a) an OX2R agonist; (b) a container containing an agent for reducing the metabolism of the OX2R agonist; and (c) instructions for administering (a) and (b).

[0146] The kits disclosed herein may further comprise an additional container containing saline.

[0147] The container can be a glass vial. Alternatively, the container can be a syringe.

[0148] The present disclosure should not be limited by the specific embodiments described herein, which are intended as single illustrations of individual aspects of the disclosure. Not all of the various embodiments of the present disclosure are described herein. As will be apparent to those skilled in the art, many modifications and variations can be made to the present disclosure without departing from its spirit and scope. Functionally equivalent methods and apparatuses falling within the scope of the present disclosure, in addition to those recited herein, will be apparent to those skilled in the art from the above description. Such modifications and variations are intended to be included within the scope of the appended claims. The present disclosure is to be limited only by the appended claims, along with the full scope of equivalents to which such claims are entitled.

[0149] It is to be understood that this disclosure is not limited to particular uses, methods, reagents, compounds, compositions or biological systems, which can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

[0150] Additionally, when features or aspects of the present disclosure are described in terms of Markush groups, those skilled in the art will recognize that the present disclosure is also thereby described in terms of any individual members or subgroups of the Markush group.

[0151] Those skilled in the art will understand that for any and all purposes, particularly with respect to providing a written description, all ranges disclosed herein encompass any and all possible subranges and combinations of subranges. It will be readily recognized that any recited range is sufficiently descriptive and allows for the range to be broken down into at least two, three, four, five, ten, etc. divisions. By way of non-limiting example, each range discussed herein can be readily broken down into a lower third, middle third, and upper third, etc. Those skilled in the art will also understand that all expressions such as "less than or equal to," "at least," "greater than," "less than," etc., refer to ranges that are inclusive of the recited numbers and that can be successively broken down into subranges as discussed above. Finally, those skilled in the art will understand that a range is inclusive of each individual component. Thus, for example, a group having 1 to 3 cells refers to a group having 1, 2, or 3 cells. Similarly, a group having 1 to 5 cells refers to a group having 1, 2, 3, 4, or 5 cells, and so on.

[0152] definition Unless otherwise defined, all scientific and technical terms used herein have the meaning commonly understood by one of ordinary skill in the art to which this disclosure belongs. The following references provide those skilled in the art with general definitions for many of the terms used in this invention: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, Harper Collins Dictionary of Biology (1991). As used herein, the following terms have the following meanings ascribed to them unless otherwise specified. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the disclosure.

[0153] As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise.

[0154] As used herein, the term "about" or "approximately" means within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which will depend to some extent on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" can mean within three or more standard deviations, according to practice in the art. Alternatively, "about" can mean within 20% or less, preferably 10% or less, more preferably 5% or less, and even more preferably 1% or less of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within 10-fold, preferably within 5-fold, and more preferably within 2-fold of a value.

[0155] As used herein, the term "administration" of an agent to a subject includes any route by which an agent can be introduced or delivered to a subject to perform its intended function. Administration can be by oral route or any suitable parenteral route, such as intravenous, intramuscular, intraperitoneal, subcutaneous, and other suitable routes described herein. Administration includes self-administration and administration by another.

[0156] As used herein, the term "effective amount" or "therapeutically effective amount" refers to the amount of compound (I) (or OX2R agonist) sufficient to produce a desired effect or a desired therapeutic effect. In the context of therapeutic use, the amount of compound (I) (or OX2R agonist) administered to a subject may depend on the type and severity of the disease (e.g., narcolepsy, narcolepsy type 1) or symptom, as well as individual characteristics such as general health, age, sex, weight, and tolerance to drugs. Those skilled in the art will be able to determine the appropriate dosage depending on these and other factors.

[0157] As used herein, the term "modulate" means to effect a positive or negative change. Exemplary modulations include a change of about 1%, about 2%, about 5%, about 10%, about 25%, about 50%, about 75%, or about 100%.

[0158] As used herein, the term "increase" means to effect a positive change of at least about 5%, including but not limited to, effecting a positive change of about 5%, about 10%, about 25%, about 30%, about 50%, about 75% or about 100%.

[0159] As used herein, the term "reduce" means to effect a negative change of at least about 5%, including, but not limited to, effecting a negative change of about 5%, about 10%, about 25%, about 30%, about 50%, about 75% or about 100%.

[0160] As used herein, the term "OX2R agonist" refers to an orexin neuropeptide agonist that acts at the orexin 2 receptor. In some embodiments, the OX2R agonist is Compound (I). In some embodiments, Compound (I) is (2R,3S)-3-((methylsulfonyl)amino)-2-(((cis-4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate methyl (hereinafter "Compound A") or a salt thereof. [Example]

[0161] The following examples are put forward so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the compositions, and assay, screening and treatment methods of the present invention, and are not intended to limit the scope of what the inventors regard as their invention.

[0162] Example 1: A Phase 1, Open-Label Study to Evaluate the Effect of Cobicistat on the Single-Dose Pharmacokinetics of Orally Administered Compound A to Healthy Subjects

[0163] The objective of this study was to evaluate the effect of cobicistat on Compound A. The primary goal was to assess whether cobicistat can enhance the plasma concentrations of oral Compound A in humans and therefore whether it can be used in combination with Compound A as part of an oral dosing regimen. The magnitude of this intended drug-drug interaction (DDI) will also be quantified.

[0164] Another objective of this study was to evaluate the time course of CYP3A inactivation by cobicistat to characterize the onset of CYP3A inhibition and the attainment of steady-state levels of inhibition.Midazolam is a benzodiazepine derivative that is metabolized exclusively by the CYP3A enzymatic pathway and therefore was used as an in vivo probe of human CYP3A activity.

[0165] Test purpose(s) 1. Primary purpose: To evaluate the effect of steady-state cobicistat on the single-dose pharmacokinetics of orally administered Compound A 2.Second purpose: To evaluate the safety and tolerability of a single oral dose of Compound A with and without cobicistat.

[0166] Test evaluation items 1. Primary endpoint Plasma PK parameters (AUC) of Compound A after oral administration with and without cobicistat ∞ , AUC last , C max ) 2. Secondary endpoints Adverse events

[0167] A brief overview of the study design

[0168] This was a non-randomized, open-label, fixed-sequence study in healthy male and female (women of non-childbearing potential [WONCBP]) subjects.

[0169] On day 1, subjects received 1 mg of midazolam orally, and pharmacokinetic (PK) blood samples for midazolam (and its metabolite, 1-hydroxy (1-OH) midazolam) were collected pre-dose and up to 24 hours post-dose to establish baseline cytochrome P450 (CYP) 3A activity. On day 2, subjects received 14 mg of Compound A via intravenous (IV) infusion over 9 hours, and PK blood samples for Compound A were collected pre-dose and up to 15 hours after the end of the infusion. On day 3, subjects received 112 mg of Compound A orally, and PK blood and urine samples for Compound A were collected pre-dose and up to 48 hours post-dose.

[0170] Subjects received 150 mg of cobicistat orally once daily (QD) on days 5-13, and PK blood samples for cobicistat were collected pre-dose on day 5 and up to 24 hours post-dose. Pre-dose blood samples for cobicistat PK were also collected on days 7, 9, 10, and 11.

[0171] On days 7 and 10, 0.5 mg of midazolam was administered orally (30 minutes after cobicistat dosing), and on each of these days PK blood samples for midazolam and 1-OH midazolam were drawn pre-dose and up to 24 hours after midazolam dosing.

[0172] On Day 12, 14 mg of Compound A was administered orally (30 minutes after Cobicistat dosing), and PK blood and urine samples for Compound A were collected pre-dose and up to 48 hours after Compound A dosing, and PK blood samples for Cobicistat were collected pre-dose and up to 24 hours after Cobicistat dosing on Day 12, and 24 hours after Cobicistat dosing on Day 13.

[0173] Safety was assessed throughout the study by tracking adverse events (AEs), vital signs, 12-lead electrocardiograms (ECGs) for safety, laboratory assessments for safety, pulse oximetry, C-SSRS (Columbia-Suicide Severity Rating Scale), and physical examinations.

[0174] A summary of the overall study design is shown in Figure 1.

[0175] [Table 1-1]

[0176] [Table 1-2]

[0177] Study population

[0178] Healthy male and female subjects aged 19 to 55 years, including the end point, at screening. 18.0 to 32.0 kg / m2, including the end point, at screening. 2 is the Body Mass Index (BMI).

[0179] Key inclusion criteria Healthy adult men or women (without potential pregnancy) aged 19–55 years, inclusive, at the time of screening. Continuous non-smokers who have not used nicotine-containing products for at least 90 days prior to first dose and throughout the study. 18.0 kg / m including endpoints at screening 2 More than 32.0kg / m 2 Body mass index (BMI) that is less than or equal to: · Medically healthy with no clinically significant medical history, physical exam, laboratory profile, vital signs, or ECG, as determined by the investigator or designee.

[0180] Key Exclusion Criteria · Was mentally or legally unfit, or had significant emotional problems at the time of the screening visit or anticipated during the conduct of the study. · History or presence of any clinically significant medical or psychiatric condition or illness, in the opinion of the investigator or designee. Any medical history that, in the opinion of the investigator or designee, could confound the results of the study or place the subject at additional risk due to the subject's participation in the study. · History or presence of alcoholism or drug abuse within the past 2 years prior to the first dose, according to Diagnostic and Statistical Manual of Mental Disorders-V criteria. · You are unable or expect to refrain from using: Any medications known to be significant inducers or inhibitors of the CYP3A4 enzyme and / or P-gp, including St. John's wort, within 28 days prior to the first dose, throughout the study, and up until the follow-up visit. Appropriate sources (e.g., Flockhart Table™) were consulted to confirm the absence of PK / pharmacodynamic interactions with the study drug(s). Any medications, including prescription and nonprescription drugs, herbal remedies, antacids, or vitamin supplements, within the 28 days prior to the first dose, throughout the study, and up until the follow-up visit. Product labels were inspected to ensure there were no serious drug interactions [TYBOST® 2018]. After the first dose, acetaminophen (up to 2 g per 24 hours) may have been administered at the discretion of the investigator or designee. Thyroid hormone replacement medication may have been permitted if the subject had received such a stable dose for the last 3 months prior to the first dose.

[0181] Key criteria for evaluation and analysis

[0182] Primary endpoint of the study: Plasma pharmacokinetic parameters of Compound A after oral administration with and without cobicistat are as follows: Maximum observed concentration (Cmax). Area under the concentration-time curve from time 0 to infinity (AUCinf), calculated using the actual measured value of the final quantifiable concentration. Area under the concentration-time curve from time 0 to the time of the last quantifiable concentration (AUClast).

[0183] Blood PK Sampling for Compound A: Study Day 2: Pre-dose (before starting IV infusion of Compound A), 1, 2, 4, 9, 9, 17, 10, and 13 hours after starting the infusion. Day 3 of the study: 24 hours after dosing on Day 2 (before dosing (before oral administration of Compound A)), and 0.17, 0.33, 0.5, 1, 2, 4, 6, 9, and 12 hours after dosing Day 4: 24 and 36 hours after the day 3 dose Study Day 5: 48 hours after dosing on Day 3 and before cobicistat administration Study days 12-14: Pre-dose (before oral administration of cobicistat and Compound A), and 0.17, 0.33, 0.5, 1, 2, 4, 6, 9, 12, 24, 36, and 48 hours after oral administration of Compound A

[0184] Blood PK Sampling for Cobicistat: Day 5: Pre-dose (before cobicistat administration) and 0.5, 1, 2, 4, 6, 9, and 12 hours after dosing Day 6: 24 hours after dosing on Day 5 and before cobicistat administration Day 7: Pre-dose (before administering cobicistat and midazolam) Day 9: Pre-dose (before administering cobicistat) Day 10: Pre-dose (before administering cobicistat and midazolam) Day 11: Pre-dose (before administering cobicistat) Study Day 12: Pre-dose (before oral administration of cobicistat and Compound A), and 0.5, 1, 2, 4, 6, 9, and 12 hours after cobicistat administration Day 13: 24 hours after dosing on Day 12 and before cobicistat administration Day 14: 24 hours after dosing on Day 13

[0185] Blood PK Sampling for Midazolam and Its Metabolite (1-Hydroxymidazolam): Day 1: Before administration (before midazolam administration), 0.5, 1, 1.5, 2, 4, 6, 8, and 12 hours after administration Study Day 2: 24 hours after dosing on Day 1 and before the start of IV infusion of Compound A Day 7: Pre-dose (before cobicistat and midazolam administration), 0.5, 1, 1.5, 2, 4, 6, 8, and 12 hours after midazolam administration Study Day 8: 24 hours after midazolam administration on Day 7 and before cobicistat administration Day 10: Pre-dose (before administration of cobicistat and midazolam), 0.5, 1, 1.5, 2, 4, 6, 8, and 12 hours after midazolam administration Study Day 11: 24 hours after midazolam administration on Day 10 and before cobicistat administration

[0186] PK parameter analysis:

[0187] Plasma pharmacokinetic parameters (Cmax, AUCinf and AUClast) of Compound A after oral administration with and without cobicistat were calculated.

[0188] A summary of the statistical comparison of dose-normalized plasma Compound A PK in healthy subjects after 112 mg oral Compound A alone on day 3 and 14 mg oral Compound A plus multiple doses of 150 mg cobicistat on day 12 is shown in Table 2.

[0189] [Table 2]

[0190] Results showed that the dose-normalized Cmax, AUCinf, and AUClast of plasma Compound A were much higher after 14 mg oral Compound A plus multiple doses of 150 mg cobicistat on day 12 compared to 112 mg oral Compound A alone on day 3.

[0191] In healthy subjects, the arithmetic mean plasma concentration-time profiles of Compound A after 14 mg Compound A IV alone on day 2, 112 mg Compound A orally alone on day 3, and 14 mg Compound A orally plus multiple doses of 150 mg Cobicistat on day 12 are shown on a semi-log scale in Figure 2, normalized to the 112 mg Compound A dose, and in Figure 3, unnormalized.

[0192] Pharmacokinetic results

[0193] Compound A in plasma After dose normalization to 112 mg, coadministration of 14 mg oral Compound A plus 150 mg QD cobicistat increased the geometric least squares mean (LSM) Cmax and AUC (AUClast and AUC∞) of Compound A by approximately 50-fold and 109-fold, respectively, compared to the corresponding values ​​after 112 mg oral Compound A alone. The geometric mean dose-normalized Cmax and AUC∞ of Compound A after 112 mg oral Compound A alone was approximately 84% and 97% lower, respectively, compared to 14 mg IV Compound A alone. The geometric mean dose-normalized Cmax and AUC∞ of Compound A following 14 mg Compound A oral + 150 mg QD cobicistat were increased by 7.9-fold and 2.8-fold, respectively, compared to 14 mg Compound A IV alone (IV infusion over 9 hours). Co-administration of 14 mg oral Compound A with 150 mg QD cobicistat prolonged the mean t1 / 2z of Compound A to approximately 8 hours compared to 4.9 hours after 112 mg oral Compound A alone and 3.7 hours after 14 mg IV Compound A alone.

[0194] Plasma midazolam Cobicistat increased midazolam Cmax to a similar extent on days 7 and 10, and was approximately 5-fold higher than the corresponding value obtained after 1 mg midazolam alone on day 5. Cobicistat increased midazolam AUC∞ to similar extents on days 7 and 10, and was approximately 25- to 27-fold higher than the corresponding values ​​obtained after 1 mg midazolam alone on day 5.

[0195] conclusion In healthy adult subjects, cobicistat, through potent CYP3A inhibition, significantly increased the systemic exposure of orally administered Compound A. When accompanied by steady-state cobicistat, a single oral dose of Compound A generally appeared to be safe and well tolerated by healthy adult subjects in this study.

Claims

1. In the manufacture of a medicament for improving the pharmacokinetics of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof, (a) methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof, and (b) CYP3A4 inhibitor Use of a combination of.

2. In the manufacture of a medicament for increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof, (a) methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof, and (b) CYP3A4 inhibitor Use of a combination of.

3. In the manufacture of a medicament for increasing wakefulness or reducing excessive sleepiness in a subject in need thereof, (a) methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof, and (b) CYP3A4 inhibitor Use of a combination of.

4. The use according to any one of claims 1 to 3, wherein the CYP3A4 inhibitor is selected from the group consisting of ritonavir and cobicistat.

5. 5. The use according to claim 4, wherein the CYP3A4 inhibitor is cobicistat.

6. The use according to any one of claims 1 to 5, wherein (a) is administered by oral administration.

7. The use according to any one of claims 1 to 6, wherein (a) is administered daily.

8. 8. The use of claim 7, wherein (a) is administered as a single daily dose or multiple daily doses.

9. The use according to any one of claims 1 to 3, wherein the CYP3A4 inhibitor is administered daily.

10. 10. The use of claim 9, wherein the CYP3A4 inhibitor is administered as a single daily dose or multiple daily doses.

11. The use according to any one of claims 1 to 3, wherein the CYP3A4 inhibitor is administered after administration of (a).

12. The use according to any one of claims 1 to 3, wherein the CYP3A4 inhibitor is administered prior to the administration of (a).

13. The use according to any one of claims 1 to 3, wherein the CYP3A4 inhibitor is administered simultaneously with (a).

14. The use according to any one of claims 1 to 13, wherein (a) is an optically active compound.

15. The use according to claim 14, wherein (a) is methyl (2R,3S)-3-((methylsulfonyl)amino)-2-(((cis-4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof.

16. (a) methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof, and (b) CYP3A4 inhibitor A composition comprising:

17. 17. The composition of claim 16, wherein the CYP3A4 inhibitor is selected from the group consisting of ritonavir and cobicistat.

18. 17. The composition of claim 16, wherein the CYP3A4 inhibitor is cobicistat.

19. The composition according to any one of claims 16 to 18, wherein (a) is an optically active compound.

20. The composition of claim 19, wherein (a) is methyl (2R,3S)-3-((methylsulfonyl)amino)-2-(((cis-4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof.

21. The use according to any one of claims 1 to 3, wherein the (2R,3S)-3-((methylsulfonyl)amino)-2-(((cis-4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof is administered in an amount of about 5 mg to about 50 mg.

22. The use of claim 5, wherein the cobicistat is administered in an amount of about 100 mg to about 200 mg.

23. The use described in any one of claims 1 to 3, wherein the CYP3A4 inhibitor is ritonavir and the ritonavir is administered in an amount of about 25 mg to about 100 mg.

Images